We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

NIH Renews Genomatix License

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Genomatix Software GmbH has renewed its license agreement with the NCI (National Cancer Institute) under which NIH (National Institutes of Health) intramural researchers nation wide do have full access to the Genomatix suite of software tools and databases. The new license includes Genomatix' ChipInspector which will be released later this year. ChipInspector, as well as all the other Genomatix products, recently have been awarded with the "Gene Chip Compatible" status from Affymetrix Inc. ChipInspector allows for single probe chip analysis, including latest up to date genome information from Genomatix’ ElDorado genomic annotation engine.

Applying the full Genomatix chip analysis pipeline to a researcher's microarray results raw data strongly enhances the identification of significantly changed transcripts, generates the full biological network of involved genes, and allows for functional analysis of the sub-networks most relevant for the experimental set-up. Downstream analysis looks for common promoter organization being responsible for co-regulation of involved genes. Large scale genomic database scanning with such organizational patterns identifies additional genes belonging to a common regulatory environment.

Dr. Martin Seifert, Vice President of Microarray Business at Genomatix stated: "I am very happy that the renowned experts from the NIH will be among the first non-Genomatix scientists who will have access to ChipInspector and our entire chip analysis pipeline. I am very keen to see high level scientific results and expect a boost of new publications citing our tools"